Circular RNAs as a novel molecular mechanism in diagnosis, prognosis, therapeutic target, and inhibiting chemoresistance in breast cancer.
Nafiseh TashakoriMaria V MikhailovaZainab Abbas MohammedaliMorug Salih MahdiAli M Ali Al-NuaimiUsama Kadem RadiAbdullateff Mohammad AlfarajBahman Abedi KiasariPublished in: Pathology, research and practice (2024)
Breast cancer (BC) is the most common cancer among women, characterized by significant heterogeneity. Diagnosis of the disease in the early stages and appropriate treatment plays a crucial role for these patients. Despite the available treatments, many patients due to drug resistance do not receive proper treatments. Recently, circular RNAs (circRNAs), a type of non-coding RNAs (ncRNAs), have been discovered to be involved in the progression and resistance to drugs in BC. CircRNAs can promote or inhibit malignant cells by their function. Numerous circRNAs have been discovered to be involved in the proliferation, invasion, and migration of tumor cells, as well as the progression, pathogenesis, tumor metastasis, and drug resistance of BC. Circular RNAs can also serve as a biomarker for diagnosing, predicting prognosis, and targeting therapy. In this review, we present an outline of the variations in circRNAs expression in various BCs, the functional pathways, their impact on the condition, and their uses in clinical applications.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- signaling pathway
- peritoneal dialysis
- type diabetes
- poor prognosis
- induced apoptosis
- metabolic syndrome
- pregnant women
- squamous cell carcinoma
- oxidative stress
- cell proliferation
- drug delivery
- mesenchymal stem cells
- binding protein
- breast cancer risk
- childhood cancer
- smoking cessation
- cell therapy
- pi k akt